EuroPCR 2022 | 1 Year Outcomes of Tricuspid Valve Repair with Cardioband: Feasibility Study

Tricuspid failure is a prevalent valvulopathy most often mistreated. It has been associated with high surgical risk and medical treatment has showed substandard therapeutic effect.

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

Surgical repair with valve annuloplasty is the technique of choice for its long-term durability. Transcatheter repair of the tricuspid valve is an alternative that aims at imitating annuloplasty by reducing annulus diameter to facilitate better valve coaptation. 

A multicenter single arm study was conducted aiming at assessing the effectiveness and safety of the Cardioband safety system in the treatment of functional tricuspid failure

37 patients with tricuspid failure were included, at least moderate, symptomatic despite optimal medical treatment, with appropriate anatomy for the procedure. 

Primary end point was absence of adverse events associated to the procedure at 30 days, followed up for one year.  

Read also: EuroPCR 2022 | The IMPROVED-CTO Trial.

Patients were mean age 78±7.5, 76% were women, all of them presented severe tricuspid failure (60% torrential) and 73% pulmonary hypertension. 

When looking at major cardiovascular events, there was 8% cardiovascular mortality (unrelated to the procedure) mainly high rate of severe bleeding, both at 30 days (21%) and one year (35%), and 10% of rehospitalization for cardiac failure. 

The technique was shown effective, with 21% tricuspid annulus diameter reduction, which meant 73% reduction in tricuspid failure moderate to severe. Functional class was also improved (dyspnea in functional class CF I or II in 92% of patients).

Conclusions

Tricuspid repair with Cardioband showed high survival rate with low number of hospitalizations for cardiac failure. At one-year followup, there was significant tricuspid failure reduction and improved quality of life compared to baseline values. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Source: Presented by Late-breaking clinical trial en EuroPCR 2022 por Dr William Gray.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...